Krystal Biotech, Inc. (KRYS) NASDAQ
293.21
-4.89(-1.64%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
293.21
-4.89(-1.64%)
Currency In USD
| Previous Close | 298.1 |
| Open | 293.01 |
| Day High | 297 |
| Day Low | 285.07 |
| 52-Week High | 319.48 |
| 52-Week Low | 127.99 |
| Volume | 333,927 |
| Average Volume | 278,806 |
| Market Cap | 8.64B |
| PE | 39.2 |
| EPS | 7.48 |
| Moving Average 50 Days | 279.07 |
| Moving Average 200 Days | 233.99 |
| Change | -4.89 |
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
GlobeNewswire Inc.
Feb 10, 2026 1:00 PM GMT
PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S.
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
GlobeNewswire Inc.
Feb 09, 2026 1:00 PM GMT
PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707,